Tumor-associated macrophages in multiple myeloma: advances in biology and therapy

Jennifer Sun,1,2 Chaelee Park,1 Nicole Guenthner,1 Shannon Gurley,1 Luna Zhang,1,2 Berit Lubben,1 Ola Adebayo,1 Hannah Bash,1 Yixuan Chen,1 Mina Maksimos,1 Barbara Muz,1 Abdel Kareem Azab1,2

ABSTRACT
Multiple myeloma (MM) is a cancer of plasma cells in the bone marrow (BM) and represents the second most common hematological malignancy in the world. The MM tumor microenvironment (TME) within the BM niche consists of a wide range of elements which play important roles in supporting MM disease progression, survival, proliferation, angiogenesis, as well as drug resistance. Together, the TME fosters an immunosuppressive environment in which immune recognition and response are repressed. Macrophages are a central player in the immune system with diverse functions, and it has been long established that macrophages play a critical role in both inducing direct and indirect immune responses in cancer. Tumor-associated macrophages (TAMs) are a major population of cells in the tumor site. Rather than contributing to the immune response against tumor cells, TAMs in many cancers are found to exhibit protumor properties including supporting chemoresistance, tumor proliferation and survival, angiogenesis, immunosuppression, and metastasis. Targeting TAMs represents a novel strategy for cancer immunotherapy, which has potential to indirectly stimulate cytotoxic T cell activation and recruitment, and synergize with checkpoint inhibitors and chemotherapies. In this review, we will provide an updated and comprehensive overview into the current knowledge on the roles of TAMs in MM, as well as the therapeutic targets that are being explored as macrophage-targeted immunotherapy for MM.

INTRODUCTION
The bone marrow (BM) microenvironment plays a key role in the development and progression of multiple myeloma (MM). Tumor-associated macrophages (TAMs) within the BM niche have recently captured the attention of researchers as a potential therapeutic target, given the plasticity and range of functionality inherent to this cell type. Prior reviews focusing on TAMs in MM have discussed mechanisms of action for which they support MM progression, as well as potential treatment options for other forms of malignancies that take advantage of these macrophages.1-4 In this review, we will provide updated and comprehensive insight into the current knowledge on the roles of TAMs, as well as the therapeutic targets that are being explored as macrophage-targeted immunotherapy for MM.

Multiple myeloma
MM is a cancer of plasma cells in the BM and represents the second most common hematological malignancy in the world.3 In the past decade, therapeutic breakthroughs such as proteasome inhibitors (PIs), immunomodulatory drugs, and antibody-based therapeutics have substantially expanded the number of treatment regimens available for patients in all stages of MM.6 However, MM remains to be incurable because almost all patients eventually relapse and/or become refractory to treatment, and relapsed/refractory MM (RRMM) has a lowered median survival of only 5–15 months.7 Development of MM is preceded by two asymptomatic precursor stages—monoclonal gammopathy of undetermined significance (MGUS) and smoldering MM (SMM). The transition between healthy cells, MGUS, SMM, and MM, as well as the progression of MM, are heavily influenced by the development of the BM niche.8 The MM tumor microenvironment (TME) within the BM niche consists of a wide range of elements such as hematopoietic stem cells, progenitor cells, mesenchymal stromal cells, endothelial cells, immune cells, osteoblasts, osteoclasts, adipocytes, extracellular matrix proteins, and growth factors.9,10 TME components have been shown to play important roles in supporting MM disease on multiple levels, including MM progression, survival, proliferation, angiogenesis, as well as drug resistance.8,11,12 Together, the TME fosters an immunosuppressive environment in which
Immune recognition and response are repressed.13–15 Therefore, the BM niche is home to promising therapeutic targets for MM, and targeted reprogramming of protumor TME components may hold key to future therapeutics for MM. This review focuses on the crosstalk between macrophages and MM tumor cells, which have been a particularly promising area of study for MM and other malignancies.

Macrophage polarization and functions

Macrophages are a major component of the innate immune system and can be found across tissue types.16 The origin of tissue macrophages vary; some residual macrophages derive from embryonic yolk sac or fetal liver, while the adult macrophage population are understood to derived from the monocyte precursor through hematopoiesis.17 Mature macrophages in the human body are identifiable by the CD68, CD163, CD16, CD312, and CD115 markers.16 18

Macrophages are recognized for their wide variety of functions19; they are especially well known for their ability to phagocytose pathogens and apoptotic cells, but their contribution to the immunity and homeostasis of the body goes far beyond phagocytosis.20 Macrophages are highly plastic, and can activate and polarize for a specific role depending on environmental cues.21 It is widely accepted that polarized macrophages can be classified on a spectrum of M1 and M2 phenotypes.

The classically activated M1 macrophages, which are stimulated by interferon-γ (IFNγ) or lipopolysaccharide, are identifiable by their proinflammatory properties and are involved in the phagocytic and immune response.22 M1 macrophages express inducible nitric oxide synthase and reactive oxygen species, which are both proinflammatory and aid in the killing of pathogens.23 24 These activated macrophages release inflammatory cytokines such as interleukin (IL)-1, IL-6, IL-8, IL-12, and tumor-necrosis factor α (TNFα) that aid in the immune response.21 The M1 proinflammatory macrophages are also known to be professional antigen-presenting cells (APCs), where they phagocytose and present fragments of antigen on its surface major histocompatibility complex (MHC) class II, bridging to the adaptive immune system for a more efficient recognition of pathogens.18

The alternatively activated M2 macrophages are stimulated by IL-4. They are anti-inflammatory and participate in immunosuppression and wound healing. They secrete vascular endothelial growth factor (VEGF) and transforming growth factor-β (TGF-β) which promote angiogenesis and fibroblast activation at the wound site.25 26 Unlike M1 macrophages, M2 macrophages have minimal antigen-presenting ability. Variations in M2 macrophages have been observed in vitro, suggesting that M2 macrophages can be subdivided into M2a, M2b, or M2c subtypes, thoroughly reviewed elsewhere.27

Tumor-associated macrophages

TAMs are considered by their surface markers CD163 and CD206, expression of arginase, as well as production of VEGF, IL-10, and matrix metalloproteinases (MMPs).30 Due to their striking similarity in function and phenotype, TAMs are often paralleled with M2-like macrophages.31 TAMs secrete immunosuppressive cytokines such as IL-10 and TGF-β, which combine to reduce T cell functionality and contribute to the immunosuppressive TME.32

THE ROLE OF TAMs IN MM

TAMs are a significant component in the BM of MM patients, constituting around 10% of the BM.33 The prevalence of TAMs in MM has resulted in heightened attention invested into understanding the interplay between MM cells and TAMs in order to identify novel immunotherapy targets. In this section, we will comprehensively discuss the various ways that TAMs influence MM pathophysiology, including proliferation and survival, angiogenesis, immunosuppression, and drug resistance (figure 1).

MM proliferation and survival

The MM TAMs in the BM microenvironment have been reported to heavily support MM proliferation and survival. Increased infiltration of macrophages to the tumor site is characteristic in MM patients compared with healthy subjects, and that heightened number of CD163 or CD206 TAMs is a negative prognosis marker in MM patients.34 35 Additionally, in a recent effort to identify the immune landscape in various stages of MM, it was shown that TAMs numbers dramatically increase in patients with an aggressive form of MM.36 It was also revealed that TAMs were among the most correleatef informational marker for therapeutic response in patients who underwent standard-of-care chemotherapy treatment; patients not achieving complete remission had higher frequencies of TAMs, and the response to treatment positively correlated with the number of TAMs at time of diagnosis.36

Additionally, soluble CD163 in patient serum was associated with poor survival outcomes; the BM microenvironment had localized production of soluble CD163, further indicating the importance of macrophages in supporting MM proliferation and survival outcomes.37

Mode of action behind TAM-supported MM growth has also been extensively explored under controllable conditions using murine and cell line models. Multiple
mechanisms have been revealed regarding TAM supported MM proliferation, especially through prolific secretion and regulation of various cytokines. Most notably, TAMs have heightened IL-6 and IL-10 secretions, and inhibited IL-12 and TNF-α secretions.38

IL-6 is a key cytokine that has pleiotropic functions in both inflammation and immunity. In the context of cancer, IL-6 has been shown to be critical for providing survival benefits to variety of tumor types.39 In MM patients, elevated IL-6 level correlates with adverse prognosis.40 Additionally, IL-6-deficient mice were completely resistance to disease development, showing the essential role of IL-6 in myeloma growth and survival.41 Ex vivo interrogation revealed myeloid cells being the major IL-6 secreting cell type in the TME; in vitro data demonstrated that TAMs support MM cell survival through activation of the IL-6/JAK/STAT3 pathway.42 Coculture of TAMs with 5T33MM murine MM cells provided survival benefits for the myeloma cells, mediated through activation of STAT3 pathway in 5T33MM cells.43 STAT3 has also been shown to be phosphorylated at a higher level in CD11b+ cells of MM-bearing mice compared with naïve mice.45 Thus, the interplay of JAK/STAT activation in both MM and TAMs relates to MM survival and pathogenesis.

Furthermore, it has been reported that IL-6 leads to the production of IL-10, which also plays an important role in the survival and proliferation of MM.38,46 In MM patients, high IL-10 serum level correlates with disease prognosis,47 suggesting IL-10’s clinical significance in MM pathogenesis and progression.

**Angiogenesis**

Proximity to vasculature is necessary for proliferation and survival of MM by providing oxygen and nutrients.
BM neovascularization in MM supports disease progression, and more evidence has been recovered to suggest that TAMs in the BM microenvironment play a role through angiogenic and vasculogenic activities. CD206^+/Tie2^+macrophages are found to correlate with increased proangiogenic cytokines and microvessel density in an MM mouse model. IL-10 secreted by MM-associated TAMs positively correlates with angiogenic cyto-
like vessels. Thus, macrophages aid in angiogenesis in acquiring endothelial cell markers and forming capillar
fiberblast growth factor began to mimic vasculature by production of proinflammator
in turn limit effector T cell functions. On the other hand, macrophages can also express and secrete angiogenic factors, such as VEGF, CCLs, and MMPs.
It was reported that TAMs and MM cells could synergistically promote human umbilical vein endothelial cells (HUVECs) proliferation, migration, and tube formation in vitro, and that VEGFA released from both cell types was crucial to HUVEC tube formation ability. Additionally, MM-associated macrophages exposed to VEGF and basic fibroblast growth factor began to mimic vasculature by acquiring endothelial cell markers and forming capillary-like vessels. Thus, macrophages aid in angiogenesis in MM through both direct and indirect means.

**Immunosuppression**

In addition to promoting tumor progression and angiogenesis, TAMs are also known to directly influence the development of an immunosuppressive TME in many cancer types. As a member of the innate immune system, macrophages are essential in coordinating with the adaptive immune system. Evidence has been reported that TAMs participate in modifying immune cells to increase presence of immunosuppressive cell types while decreasing antitumor cell types. In MM, a few mecha-
nisms have been reported, mainly pertaining to suppres-
ion of effector T cell activity.

MM-primed macrophages decreased T cell prolifer-
ation and activation, through downregulation of IFN-γ secretion. In a recent effort investigating BM immune landscape changes in MM disease stages compared with healthy donors using single-cell RNA sequencing, it was revealed that dysregulation of MHC class II in CD14^+ monocytes conferred T cell suppression.

IL-10 is a key immunosuppressive cytokine mainly secreted by myeloma-associated macrophages that participates in an array of tumor supportive activities, such as tumor growth, angiogenesis, and disease progression. IL-10 is known to inhibit expression of MHC class II and production of proinflammatory cytokines in APCs, which in turn limit effector T cell functions.

Indoleamine 2,3-dioxygenase (IDO) is an enzyme that degrades the essential amino acid tryptophan into kynurenine. IDO is known to inhibit effector T cells and promote differentiation of T regulatory cells (Tregs), thus inhibiting the immune response. In MM, MM secreted IL-32 increases production of IDO in macrophages, which inhibits immunogenic response through inhibition of CD4^+ T cell growth, IL-2, IFNγ, and TNFα production.

Finally, macrophages play a direct part in immune evasion via the macrophage immune checkpoint CD47-
SIRPα. It has been shown that many solid and hematologi-
cal malignancies overexpress the CD47 protein on the surface as a protective ‘self-marker’. Binding of CD47 to signal-regulatory protein alpha (SIRPα) receptor on the surface of macrophages leads to downstream signaling within the macrophages, resulting in inhibition of phago-
cytosis activity, thus the CD47-SIRPα interaction is also known as the ‘don’t-eat-me’ signal. In MM, CD47 is overexpressed in CD138^+ primary tumor cells compared with normal BM cells, and positively correlates with the stage of the disease, which lead to impaired immune recognition.

In summary, MM-associated macrophages secrete signaling molecules that consequently suppress T cell functions, in addition to actively participate in the CD47-
SIRPα checkpoint.

**MM drug resistance**

One of the greatest difficulties with MM from a clinical standpoint is its tendency to develop resistance to treatment and relapse. In a clinical study, high TAM frequencies in the patient MM BM was found to negatively correlate with patient survival outcome with dexamethasone-containing chemotherapy. An increasing amount of research has been dedicated to seeking resistance mecha-
nisms toward anti-MM drugs with contributions from MM TAMs.

Macrophages enable drug resistance in MM through both signaling and molecular contact based mechanisms. One mechanism for resilience toward bortezomib is through TAM secreted IL-1β, which resulted in increased number of MM-tumor-initiating cells. It was found that there was also an increase in the total number of proinflammatory macrophages (CD68^+ /CCR2^+ in human and F4/80^+/CD11c^+ in mice) within the BM following borte-
zomib exposure. Another mechanism for bortezomib resistance was identified to be expression of B-cell activat-
ing factor (BAFF) by MM-influenced macrophages. BAFF was shown to activate MM survival through classical and alternative NF-kB pathways, which prevented borte-
zomib induced apoptosis.

Additionally, contact-based mechanisms have also been reported. Myeloma/macrophage interaction pairs, P-selectin glycoprotein ligand-1 (PSGL-1) / P-selectin and ICAM-1 / CD18, were reported to mediate resistance to melphalan.

Furthermore, macrophages also appear to respond to factors from the TME to help MM resist drug treatment. For instance, the CCL2 chemokine not only recruits macrophages and triggers their polarization to the M2 phenotype, but also stimulates macrophages to express the monocyte chemoattractant protein (MCP)-1-
induced protein (MCP1P1), which improves protection of myeloma from bortezomib-induced apoptosis.
Cancer immunotherapies targeting immune cells or the interplay of immune and cancer cells have taken center stage in oncology research. T cell-targeted immunotherapies have transformed the treatment landscape for many cancers; however, these therapies are often limited by variable patient responses.

As more evidence uncovers the crucial role of macrophages in MM pathogenesis, efforts have been made to target MM-associated macrophages as a therapeutic approach to MM. A great number of strategies have been explored to target TAMs in a variety of cancers to overcome immunosuppressive barriers. Increasing numbers of preclinical studies are directed at blocking protumor functions of TAMs and/or promoting their antitumor activities.

In this section, we will discuss different strategies used to counteract macrophages’ supportive role in progression of MM, including reducing TAMs, reprogramming TAMs, inhibiting CD47/SIRPα checkpoint, overcoming immunosuppression, and reversing drug resistance (figure 2).

Reducing TAMs

Reducing the number of macrophages by direct killing is one strategy to reduce macrophage tumor support. Direct depletion of BM resident macrophages by clodronate-liposome administration before cancer cell inoculation resulted in impaired MM cell homing and tumor development. Moreover, a single dose of the clodronate-liposome led to a significant reduction of tumor burden in a C57BL/KaLwRijHsd murine model, suggesting that direct depletion of BM macrophages is a promising strategy for treatment of MM.

In contrast to direct killing of TAMs, controlling monocyte recruitment to the tumor and therefore reducing TAM replenishment is more extensively explored. The recruitment of monocytes/macrophages into tumors is primarily regulated by cytokines, chemokines, and growth factors that are derived from tumor and stromal cells in the TME.

CXCL12-CXCR4 signaling is an important macrophage recruitment mechanism to the MM BM. Research has shown that MM cells highly express the chemokine CXCL12; the CXCR4/CXCL12 axis not only contributes to MM cell adhesion and migration, but also promotes monocyte recruitment and differentiation toward a proangiogenic and immunosuppressive M2-like phenotype with heightened CD206 expression and IL-10 production. Inhibition of CXCR4 with a neutralizing antibody significantly suppressed monocyte recruitment to the BM.

The CC chemokines are demonstrated to be crucial for macrophage infiltration in various types of cancers. CCL2, also well known as MCP-1, is a major player in driving chemotaxis of myeloid and lymphoid cells. It also maintains a scope of functions in various diseases beyond migration, making it an attractive therapeutic target. In MM, evidence shows that CCL2 is responsible for macrophage homing to the BM, as well as proliferation and polarization. Recently, it was demonstrated that MM-secreted CCL2 in the microenvironment elicits immunosuppressive MCP-1-induced protein (MCPiP1) expression in macrophages via the JAK2-STAT3 pathway, which promotes polarization toward the M2-like phenotype and protects MM cells from chemotherapyn-induced apoptosis. Inhibition of CCR2 receptor using
a monoclonal antibody (mAb) disrupted this protective effect.\textsuperscript{68} Targeting the CCR2/CCL2 axis has shown significant promise, preclinically and clinically, for blocking TAM recruitment in many cancer types including liver, pancreatic, and bladder cancers.\textsuperscript{79–81} Therefore, agents such as an anti-CCL2 mAb or CCR2 antagonist could be promising for disrupting macrophage recruitment in MM.

**Reprogramming TAMs**

Rather than depletion of TAMs, more targeted therapies are directed at blocking the protumor functions of TAMs, while promoting antitumor activities. Reprogramming TAMs to reduce their immunosuppressive M2 phenotype and promote their immunostimulatory M1 phenotype, represents a popular new field in MM treatment.

Gutiérrez-González et al reported a double treatment strategy in which they introduced the pro-M1 cytokine granulocyte–macrophage CSF (GM-CSF) while simultaneously blocking the pro-M2 cytokine macrophage migration inhibitory factor with an inhibitor.\textsuperscript{83} This dual treatment induced macrophage M1 genes and remarkable antitumor effects in vitro, performing better than GM-CSF treatment alone. Furthermore, this combination treatment resulted in macrophage-dependent therapeutic responses in a subcutaneous human MM cell line xenograft mouse model, in which TAMs isolated from treated mice had upregulated M1 and downregulated M2 markers compared with control animals. These results prove that fine tuning of TAMs polarization toward antitumor phenotype is a promising strategy for treatment of MM.\textsuperscript{82}

In another report, Wang et al studied the potential of treating MM by targeting macrophages using CSF1 receptor (CSF1R)-blocking mAbs.\textsuperscript{85} In vivo, CSF1R blockade was able to inhibit MM growth by partially depleting MM-associated macrophages and polarizing them to the M1 phenotype, as well as inducing a tumor-specific CD4+ T cell response. Moreover, the combination of CSF1R blockade and bortezomib or melphalan chemotherapy displayed additive therapeutic efficacy. These results suggest that targeting macrophages with anti-CSF1R mAbs may be a promising method to reprogram these cells to promote anti-myeloma immune and chemotherapy responses in MM patients.

Additionally, a JAK1/2 inhibitor Ruxolitinib has shown promise in suppressing the M2 phenotype in macrophages through reducing Tribbles homolog 1 protein kinase expression. In this preclinical study, treatment with ruxolitinib resulted in decreased M2 and increased M1 polarization, both in vitro and in vivo, and was shown to overcome resistance to lenalidomide.\textsuperscript{84}

Targeting CD40 is another popular strategy to activate macrophages in cancer. CD40 is a cell surface costimulatory protein found on APCs and is essential for their activation.\textsuperscript{85} Agonistic CD40 antibodies is a promising treatment of cancer patients through stimulating strong activation of innate and adaptive immunity, which are under clinical investigation in the solid tumor space.\textsuperscript{86} In myeloma, a preclinical study reported a macrophage repolarizing effect using sequential CD40 activation and TLR ligation. The immunotherapy with an agonistic anti-CD40 antibody in combination with TLR agonist CpG successfully elicited innate immune response toward MM ex vivo and in vivo.\textsuperscript{87}

Lastly, targeting the underlying mechanism by which MM influence the development of TAMs represent a novel therapy. Several recent studies focused on elucidating the MM-derived elements which mediate protumor functions of MM-associated macrophages. Zhang et al showed that BMI1 protein to be a critical regulator in macrophages under MM influence.\textsuperscript{88} Sonic hedgehog secretion by myeloma was identified to be critical for BMI1 upregulation though the Hedgehog-Myc axis, and inhibitors for Hedgehog signaling attenuated BMI1 expression in macrophages. BMI1 was further demonstrated to promote macrophage proliferation and confer various promyeloma functions including angiogenesis, chemoresistance, and myeloma growth. Finally, in a 5T murine myeloma model, a BMI1 inhibitor PTC596 was able to decrease tumor burden and prolong mice survival through depletion of MM-macrophages.

We recently reported on the critical role of the IL-10/IL-10R pathway in MM-TAM interaction. IL-10 secretion from MM cells polarized macrophages toward heightened M2 phenotype, and these macrophages in turn supported MM proliferation and drug resistance. Inhibition of IL-10/IL-10R signaling between the two cell types using an IL-10R blocking antibody robustly reprogrammed TAMs to lose their M2 phenotype, in vitro, in vivo, and ex vivo. Moreover, this resulted in the reversal of TAM supported MM proliferation and overcame drug resistance toward lenalidomide and dexamethasone.\textsuperscript{89}

**Inhibiting CD47/SIRPα checkpoint**

Recently, immune checkpoints have been receiving heightened attention in the field of cancer therapy. Immune checkpoints are inhibitory mechanisms that cancer cells use to escape from recognition and killing by immune cells, effectively putting ‘breaks’ on the immune system.\textsuperscript{90} While T cell immune checkpoint therapies targeting PD-1/PD-L1 and CTLA-4 have shown progress in various cancers, it has not been effective in treating MM.\textsuperscript{91} Hence, targeting immune checkpoints in other immune cells such as macrophages has been a topic of discussion.

We and others have explored targeting CD47 using anti-CD47 mAbs to reverse immune suppression and enhance macrophage mediated phagocytosis and killing in MM.\textsuperscript{92–94} A plethora of CD47 targeting agents are under clinical investigations, including anti-CD47 mAbs and SIRPα fusion proteins.\textsuperscript{94}

TTI-621 is a SIRPα-IgG1 Fc fusion protein being investigated in hematological malignancies in a phase Ib clinical trial (NCT02663518). In a preclinical study, TTI-621 effectively triggered macrophage-mediated
phagocytosis of MM cells. In an MM xenograft model, it showed antitumor effects and further improved efficacy when combined with PI drugs bortezomib or carfilzomib.95

Similarly, the TTI-622 SIRPα-IgG4 Fc fusion protein is also under clinical investigation in phase 1a/1b study for advanced relapsed or refractory lymphoma or myeloma (NCT03530683). In MM, TTI-622 is being investigated as monotherapy and as combination therapy with carfilzomib and dexamethasone. Preliminary data in lymphoma patients show the agent is well-tolerated and has dose-dependent binding, leading to cases of durable responses.96

AO-176 is a humanized IgG2 anti-CD47 mAb that showed preclinical anti-MM activity in MM xenograft models,93 and the efficacy was further demonstrated to have combination effect with other anti-MM therapies including bortezomib, daratumumab, lenalidomide, or pomalidomide. Currently, a phase 1/2 clinical study is underway to evaluate AO-176 as monotherapy and as combination with bortezomib/dexamethasone in MM patients (NCT04445701).

Another phase 1a/1b clinical trial is underway to study SRF231, a fully human anti-CD47 mAb, as a monotherapy in patients with advanced solid and hematological malignancies (NCT03512340).

Additionally, a novel microRNA-based method in controlling CD47 has been reported using miR-155, a direct regulator of CD47. MiR-155 overexpression suppressed CD47 expression on myeloma cells and induced macrophage phagocytosis, which also reversed bortezomib drug resistance in cell lines.97

In summary, inhibition of the CD47-SIRPα axis represents a promising strategy in boosting macrophage immune surveillance activity, providing a great tool to combat the immunosuppressive environment of the MM BM niche.

Overcoming immunosuppression

Recently, preclinical strategies have been explored to relieve the immunosuppressive environment through targeting macrophage-related molecules. It was reported that MM cells mediate the production of immunosuppressive IDO in macrophages, specifically through binding to proteinase 3 (PR3) found on macrophages and activation of STAT3 and NF-κB pathways.98 Knockdown of PR3 or inhibition of STAT3 and NF-κB pathways in macrophages all reduced the capacity for IDO production in vitro. Moreover, inhibition of IDO restored CD4 +T cell proliferation and anti-inflammatory cytokine production. Hence targeting pro-IDO mediators such as PR3 may be a novel treatment to overcome macrophage mediated immunosuppression. Another study directly targeted IDO with a chemical inhibitor D,L-1-methyl-tryptophan in patient primary cells, which reverted Tregs expansion and T helper type 1 inhibition that were resulted by IDO.98

Reversing drug resistance

Much evidence has been published to indicate that macrophages contribute to myeloma cell survival and resistance to chemotherapeutic drugs such as melphanal and bortezomib. In addition to previously described TAM reprogramming methods to overcome M2 TAM supported drug resistance, a few strategies have been explored to target the crosstalk between TAMs and MM to overcome drug resistance.

ICAM-1 on MM directly interacts with CD18 macrophages and is important for conferring drug resistance to MM cells.99 100 As a result, ICAM-1 has been explored as a candidate for immunotherapy in MM. BI-505 is a mAb developed against ICAM-1 to enhance macrophage activation.101 In preclinical studies, BI-505 decreased cell growth and bone damage in the SCID-hu model. The in vivo efficacy of BI-505 was macrophage dependent with pronounced recruitment of monocyte/macrophages to the diseased BM.101 In a phase 1 dose-escalation study (NCT01025206), BI-505 was overall tolerable in RRMM patients.102 However, to date, BI-505 has shown limited clinical efficacy. Phase 2 clinical trials (NCT01838369) in patients with SMM showed no clinical relevant response,103 and another phase 2 trial evaluating BI-505 in conjunction with autologous stem cell transplantation (ACST) was put on hold by the U.S. Food and Drug Administration due to cardiovascular events (NCT02756728).

The STAT3 pathway is activated within MM cells when cocultured with IL-6 producing M2-polarized macrophages. This leads to protection of MM cells from apoptosis resulted by decreased cleavage of caspase-3.94 AZD1480, a potent and competitive small-molecule inhibitor of JAK1/2 kinases, was used as a strategy to break this survival benefit. AZD1480 treatment in vitro was effective on both MM cell and myeloid cell populations, and abrogated the TAM-mediated MM cell survival by partially inhibiting resistance to bortezomib. Significant reduction of tumor load was observed with AZD1480 and bortezomib combination treatment in the murine 5T33MM model, and no significant killing of TAM populations were seen in vivo.44

To overcome macrophage-supported bortezomib resistance in myeloma, BAFF targeting by neutralizing antibody was investigated compared with bortezomib alone in a subcutaneous xenograft model. Anti-BAFF antibody in combination with bortezomib resulted in significantly delayed tumor growth compared with bortezomib alone, indicating BAFF as a favorable target for reversing bortezomib resistance in MM.66

FUTURE DIRECTIONS AND CONCLUSIONS

In recent years, immunotherapy has taken center stage in the field of cancer treatment. Modulation of the immune system to induce a durable response represents an exciting idea with potential to elicit superior efficacy than traditional therapies. Much of the current attention focuses on the engagement of T cells, with PD-1/PD-L1...
checkpoint inhibition being explored in over 3000 clinical trials. While there has been considerable success in T cell-targeted therapies, variable response and low T cell infiltration presents a road block.

Expanded investigation toward other immune players poses a novel area of research. Macrophages are crucial players of the innate immune system and present in high numbers in the TME. Thus, heightened attention is directed toward studying the role of macrophages in cancer. Increased amount of evidence reports prevalence of TAMs in various malignancies, and their tumor-supportive characteristics in promoting progression and drug resistance. Therefore, unearthing novel insights into mechanisms allowing TAMs’ tumor-promoting roles will provide new clues for future macrophage-targeted tumor therapy.

In conclusion, TAM-targeting therapy represents a promising treatment for cancer patients. This class of therapy could supplement current T cell therapies, impacting the current treatment regimen by overcoming unresponsiveness and drug resistance. More research is warranted to elucidate underlying molecular processes between macrophages, MM cells, and subpopulations of the TME, and strategies need to be verified in a clinical setting.

Table 1: Clinical investigation of immunotherapeutic strategies targeting TAMs in MM

| Strategy                      | Agent              | Description            | Clinical trial ID      | Phase       | Status     |
|-------------------------------|--------------------|------------------------|------------------------|-------------|------------|
| Reducing TAMs                 | None               |                        |                        |             |            |
| Reprogramming TAMs            | None               |                        |                        |             |            |
| Inhibiting CD47-SIRPα Checkpoint | TTI-621            | SIRPα-IgG1 Fc fusion protein | NCT02663518          | Phase I     | Recruiting |
|                               | TTI-622            | SIRPα-IgG4 Fc fusion protein | NCT03530683          | Phase Ia/ib | Recruiting |
|                               | AO-176             | Humanized IgG2 anti-CD47 mAb | NCT04445701          | Phase I/II  | Recruiting |
|                               | SRF231             | Fully human anti-CD47 mAb | NCT03512340          | Phase Ia/ib | Recruiting |
| Overcoming Immunosuppression  | BI-505             | Fully human anti-ICAM-1 mAb | NCT01025206          | Phase I     | Completed  |
|                               | BI-505             | Fully human anti-ICAM-1 mAb | NCT02756728          | Phase I/II  | Terminated |
| Reversing drug resistance     | None               |                        |                        |             |            |

mAb, monoclonal antibody; MM, multiple myeloma; SIRPα, signal regulatory protein α; TAMs, tumor-associated macrophages.
REFERENCES

1. Barerd S, Ria R, Reale A, et al. Multiple myeloma macropores: pivotal players in the tumor microenvironment. J Oncol 2013;2013:183602.

2. Ribatti D, Moschetta M, Vacca A. Macrophages in multiple myeloma. Immunol Lett 2014;161:241-4.

3. Petty AJ, Yang Y. Tumor-Associated macropores in hematologic malignancies: new insights and targeted therapies. Cells 2019;8:1526.

4. Opperman KS, Vandyke K, Psalitis PJ, et al. Macropores in myeloma: key roles and therapeutic strategies. Cancer Metastasis Rev 2021;40:273-284.

5. Rajkumar SV, Caradonna SA, et al. Macrophages in relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. Leukemia 2013;28:252-62.

6. Kumar SK, Dimopoulos MA, Kastritis E, et al. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. Leukemia 2013;28:252-62.

7. Manier S, Sacco A, Leleu X, et al. Bone marrow microenvironment in multiple myeloma progression. J Biomed Biotechnol 2012;2012:157496.

8. Kumar R, Godavathy PS, Krause DS. The bone marrow microenvironment in health and disease at a glance. J Cell Sci 2018;131:pc1201707.

9. Basak GW, Srivastava AS, Malhotra R, et al. Multiple myeloma bone marrow niche. Curr Pharm Biotechnol 2009;10:345-6.

10. Anderson KC, Carrasco RD. Pathogenesis of myeloma. Ann Rev Pathol 2011;6:249-74.

11. Ribatti D, Nico B, Vacca A. Importance of the bone marrow microenvironment in inducing the angiogenic response in multiple myeloma. Oncogene 2006;25:4257-66.

12. Fransen LE, Mula T, Lokhorst HM, et al. Immunotherapy in myeloma: how far have we come? Ther Adv Hematol 2019;10:20460271822660.

13. Feyler S, Selby PJ, Cook G. Regulating the regulators in cancer-immunosuppression in multiple myeloma (MM). Blood Rev 2013;27:155-64.

14. Giaglione C, Tibullo D, Camiole G, et al. TL14 signaling drives mesenchymal stromal cells commitment to promote tumor microenvironment transformation in multiple myeloma. Cell Death Dis 2019;10:704.

15. Guerriero J, Macropores: the road less traveled, changing anticancer therapy. Trends Mol Med 2018;24:472-89.

16. Weiskopf K, Schnoor PJ, Pang WW, et al. Myeloid cell origins, differentiation, and clinical implications. Microbiol Spectr 2016;4.

17. Qian B-Z, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell 2010;141:39-51.

18. Wynn TA, Chawla A, Pollard JW. Macrophage biology in development, homeostasis and disease. Nature 2013;496:445-55.

19. Arango Duque G, Descotes E, Macrophage cytokines: involvement in immunity and infectious diseases. Front Immunol 2014;5:491.

20. Bosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008;8:588-69.

21. Murray PJ. Macrophage polarization. Annu Rev Physiol 2017;79:541-68.

22. Xue Q, Yan Y, Zhang R, et al. Regulation of iNOS on immune cells and its role in diseases. Int J Mol Sci 2018;19:3805.
50 Alexandrakis MG, Goulidaki N, Pappa CA, et al. Interleukin-10 induces both plasma cell proliferation and angiogenesis in multiple myeloma. Pathol Oncol Res 2015;21:929–34.

51 Bellamy WT, Richter L, Frutiger Y, et al. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res 1999;59:728–33.

52 Sun M, Qiu S, Xiao Q, et al. Synergistic effects of multiple myeloma cells and tumor-associated macrophages on vascular endothelial cells in vitro. Med Oncol 2020;37:99.

53 Scavelli C, Nico B, Cirulli T, et al. Vascularogenic mimicry by bone marrow macrophages in patient with multiple myeloma. Oncogene 2008;27:663–74.

54 Liu KK, Joshi S. “Re-educating” Tumor Associated Macrophages as a Novel Immunotherapy Strategy for Neuroblastoma. Front Immunol 2020;11.

55 Beider K, Blitner H, Leiba M, et al. Multiple myeloma cells recruit tumor-supportive macrophages through the CXCR4/CXCL12 axis and promote their polarization toward the M2 phenotype. Oncotarget 2014;5:11283–96.

56 Zavidij O, Haradhvala NJ, Mouhieddine TH, et al. Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma. Nat Cancer 2020;1:493–506.

57 Rose-John S, Interleukin-6 family cytokines. Cold Spring Harb Perspect Biol 2018;10:a028415.

58 Yan H, Dong M, Liu X, et al. Multiple myeloma cell-derived IL-32γ increases the immunosuppressive function of macrophages by promoting indoleamine 2,3-dioxygenase (IDO) expression. Cancer Lett 2019;446:38–48.

59 Russ A, Hua AB, Montfort WR, et al. Blocking “don’t eat me” signal of CD47-Sirpα interaction in hematological malignancies, an in-depth review. Blood Rev 2018;32:480–90.

60 Veillette A, Chen J. Sirps-Cd47 immune checkpoint blockade in anticancer therapy. Trends Immunol 2018;39:173–84.

61 Zhan F, Hardin J, Kordsmeier B, et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 2002;99:1745–57.

62 Rendt Danielsen JM, Knudsen LM, Dahl IM, et al. Disregulation of CD47 and the ligands thrombospondin 1 and 2 in multiple myeloma. Br J Haematol 2007;138:758–60.

63 Sun J, Muz B, Alhalkah K, et al. Targeting CD47 as a novel immunotherapy for multiple myeloma. Cancers 2020;12:305.

64 Chen X, Chen J, Zhang W, et al. Prognostic value of diametrically, SIRPaα, Yang J, Qian J, et al. Neoadjuvant selicremab, an agonist CD40 antibody, induces changes in the tumor microenvironment in patients with resectable pancreatic cancer. Clin Cancer Res 2021;27:4574–86.

65 Jensen JL, Bakhtiar K, Henninger E, et al. Tumoricidal effects of macrophage-activating immunotherapy in a murine model of relapsed/refractory multiple myeloma. Cancer Immunol Res 2015;3:881–90.

66 Zhang D, Huang J, Wang F, et al. BM1 regulates multiple myeloma-associated macrophage’s pro-myeleoma functions. Cell Death Dis 2021;12:495.

67 Sun J, Muz B, Alhalkah K, et al., eds. P-079: TLR8 inhibition reprograms Tumor-Associated Macrophages and Reverses Drug Resistance in Multiple Myeloma. 18th International Myeloma Workshop Vienna, Austria, 2021.

68 Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 2015;27:450–61.

69 Lesokhin AM, Bal S, Badros AZ. Lessons learned from checkpoint blockade targeting PD-1 in multiple myeloma. Cancer Immunol Res 2019;7:1224–9.

70 Kim D, Wang J, Willingham SB, et al. Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells. Leukemia 2012;26:254–6.

71 Wilson WC, Richards J, Puro RJ, et al. AO-176, a highly differentiated clinical stage Anti-CD47 antibody, exerts potent anti-tumor activity in preclinical models of multiple myeloma as a single agent and in combination with Approved therapeutics. Blood 2020;136:1–4.

72 Sun J, Chen Y, Lubben B, et al. CD47-targeting antibodies as a novel therapeutic strategy in hematologic malignancies. Leuk Res Rep 2021;16:100268.

73 Linderoth E, Helke S, Lee V. Abstract 2653: the anti-myeloma activity of TTI-622, a CD47-Fc, a CD47-blocking immunomopietic, is enhanced when combined with a proteasome inhibitor. Cancer Res 2017;77:2653.

74 Patel K, Maris MB, Chenon BD, et al. Ongoing, first-in-human, phase 1 dose escalation study of the investigational CD47-blocker TTI-622 in patients with advanced relapsed or refractory lymphoma. Journal of Clinical Oncology 2020;38:3030.

75 Rastgoow N, Wu J, Liu A, et al. Targeting CD47/TNFαP in miR-155 overcomes drug resistance and inhibits tumor growth through induction of phagocytosis and apoptosis in multiple myeloma. Haematologica 2020;105:819–33.

76 Bonanno G, Mariotti A, Procaccia A, et al. Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma. J Transl Med 2012;10:247.

77 Sampayo MI, Vettore AL, Yamamoto M, et al. Expression of eight genes of nuclear factor-kappa B pathway in multiple myeloma using bone marrow aspirates obtained at diagnosis. Histol Histopathol 2009;24:991–7.
100 Schmidmaier R, Mörsdorf K, Baumann P, et al. Evidence for cell adhesion-mediated drug resistance of multiple myeloma cells in vivo. *Int J Biol Markers* 2006;21:218–22.

101 Veitonmäki N, Hansson M, Zhan F, et al. A human ICAM-1 antibody isolated by a function-first approach has potent macrophage-dependent antmyeloma activity in vivo. *Cancer Cell* 2013;23:502–15.

102 Hansson M, Gimsing P, Badros A, et al. A phase I dose-escalation study of antibody BI-505 in relapsed/refractory multiple myeloma. *Clin Cancer Res* 2015;21:2730–6.

103 Wichert S, Juliusson G, Johansson Åsa, et al. A single-arm, open-label, phase 2 clinical trial evaluating disease response following treatment with BI-505, a human anti-intercellular adhesion molecule-1 monoclonal antibody, in patients with smoldering multiple myeloma. *PLoS One* 2017;12:e0171205.

104 Upadhaya S, Neftelino ST, Hodge JP, et al. Combinations take centre stage in PD1/PDL1 inhibitor clinical trials. *Nat Rev Drug Discov* 2021;20:168–9.

105 Minnie SA, Kuns RD, Gartlan KH, et al. Myeloma escape after stem cell transplantation is a consequence of T-cell exhaustion and is prevented by TIGIT blockade. *Blood* 2018;132:1675–88.

106 Zhang L, Tian L, Dai X, et al. Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions. *J Hematol Oncol* 2020;13:153.

107 Klichinsky M, Ruella M, Shestova O, et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. *Nat Biotechnol* 2020;38:947–53.

108 Peng K-W, Dogan A, Vrana J, et al. Tumor-associated macrophages infiltrate plasmacytomas and can serve as cell carriers for oncolytic measles virotherapy of disseminated myeloma. *Am J Hematol* 2009;84:401–7.

109 Xiang X, Wang J, Lu D, et al. Targeting tumor-associated macrophages to synergize tumor immunotherapy. *Signal Transduct Target Ther* 2021;6:75.